Mediamedic/LinkedIn
Oct 4, 2025, 12:30
Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke